| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Promising Phase 1/2 data from combination study of vopimetostat plus daraxonrasib presented at 2026 ESMO Congress demonstrated 82% objective response rate (ORR) and 88% 9-month progression-free survival (PFS) rate in patients with 2L/3L ... |
| 23 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Disclaimer and safe harbor statement Certain statements in this presentation may be considered forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statem... |
| 11 Aug 2026 |
8-K: Other Events
Securities Registered under Registration Statement on Form S-3ASR |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data |
| 06 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 23 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
BOSTON, June 22, 2026 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appoi... |
| 10 Jun 2026 |
8-K: Entry into a Material Definitive Agreement
Tango Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement with J.P. Morgan Securities LLC (“J.P. Morgan”), Leerink Partners LLC (“Leerink Partners”) and each of the other Underwriters named in Schedule A he... |
| 08 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Exhibit 99.2 Vopimetostat and RAS(ON) combination data June 8, 2026 |
| 04 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The 2026 annual meeting of stockholders (the “Annual Meeting”) of Tango Therapeutics, Inc. (the “Company”) was held in a virtual-only format on June 4, 2026 at 9:00 a.m., Eastern Time via live webcast. Proxies were solicited pursuant to ... |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 |
| 08 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This confirms our discussions relating to the end of your at-will employment with Tango Therapeutics, Inc. (“Tango” or the “Company”), which is a termination by the Company without Cause for purposes of the Employment Agreement between y... |
| 15 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
This Employment Agreement (“Agreement”) is made between Tango Therapeutics, Inc., a Delaware corporation (the “Company”), and Matthew Gall (the “Executive”), and is effective as of April 15, 2026 (the “Effective Date”). |
| 05 Mar 2026 |
8-K: Results of Operations and Financial Condition
Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment |
| 08 Jan 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more
This Employment Agreement (“Agreement”) is made between Tango Therapeutics, Inc., a Delaware corporation (the “Company”), and Malte Peters, M.D. (the “Executive”), and is effective as of the Effective Date, as defined in Section 23 herein. |
| 05 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
BOSTON, January 5, 2026 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the app... |
| 21 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
On November 21, 2025, Tango Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Agent”), pursuant to which the Company may sell, from time to time, at its option, shar... |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition
– Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months – |
| 24 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
Tango Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement with Leerink Partners LLC (“Leerink Partners”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” whic... |
| 23 Oct 2025 |
8-K: Results of Operations and Financial Condition; Other Events
Disclaimer and safe harbor statement Certain statements in this presentation may be considered forward-looking statements. Forward-looking statements generally relate to future events, Tango’s future financial and operating performance, ... |
| 25 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Loading...